Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Annovis Bio Inc Market Cap
The Annovis Bio Inc (ANVS) share price is expected to increase by 308.58% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ANVS. Price targets range from $13 at the low end to $72 at the high end. The current analyst consensus for ANVS is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned ANVS 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Annovis Bio Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ANVS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ANVS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Reiterates | Oct 1, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Reiterates | Aug 15, 2024 |
| Jason Kolbert EF Hutton | Buy | $21 | Maintains | Aug 15, 2024 |
| Jason Kolbert EF Hutton | Buy | $21 | Initiates | Aug 13, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Reiterates | Jul 17, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Maintains | Jul 11, 2024 |
| Elemer Piros Rodman & Renshaw | Buy | $67 | Reiterates | Jul 2, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $23 | Reiterates | Jun 12, 2024 |
Rodman & Renshaw | Buy | $67 | Initiates | Jun 4, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $23 | Maintains | May 13, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $26 | Maintains | Apr 30, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Reiterates | Apr 30, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Maintains | Apr 2, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Reiterates | Mar 21, 2024 |
| Tyler Bussian Brookline Capital | Hold | $9 | Downgrade | Feb 28, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $36 | Initiates | Dec 29, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Reiterates | Nov 28, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $30 | Maintains | Nov 13, 2023 |
| Tyler Bussian Brookline Capital | Buy | $35 | Initiates | Nov 10, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $40 | Reiterates | Aug 15, 2023 |
When did it IPO
2020
Staff Count
6
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Maria L. Maccecchini Ph.D.
Market Cap
$104.4M
In 2023, ANVS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ANVS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 02 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Annovis Bio Inc. (NYSE: ANVS) has been featured in an editorial by NetworkNewsWire, part of InvestorBrandNetwork, focusing on financial news and content distribution.
Why It Matters - Annovis Bio's editorial placement in a prominent financial communications platform enhances its visibility, potentially attracting investor interest and impacting stock performance.
Thu, 03 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Annovis Bio Inc. (NYSE: ANVS) has announced a new broadcast titled “Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition,” available as of October 3, 2024.
Why It Matters - Annovis Bio's announcement highlights advancements in Alzheimer's treatment, potentially increasing its market value and attracting investor interest in biotech innovations.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Annovis Bio Inc. (NYSE: ANVS) will have its CEO, Dr. Maria L. Maccecchini, speaking at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024.
Why It Matters - Annovis Bio's participation in a major investment conference may enhance visibility and attract interest from potential investors, impacting stock performance and future funding opportunities.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Annovis Bio Inc. (NYSE: ANVS) reported positive preclinical data showing that its lead compound, buntanetap, synergizes with dulaglutide in Alzheimer's disease models.
Why It Matters - New preclinical data showing the effectiveness of Annovis Bio's lead compound combined with a known diabetes drug could enhance its value and attract investment, signaling potential breakthroughs in Alzheimer's treatment.
Wed, 24 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Annovis Bio Inc. (NYSE: ANVS) announced a U.S. patent for treating acute traumatic brain injuries with its lead drug candidate, buntanetap, enhancing its portfolio in neurodegenerative therapies.
Why It Matters - The patent issuance for bunetap's treatment of TBI can enhance Annovis Bio's market potential and competitiveness, potentially driving stock value and investor interest in the company.
Wed, 03 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Annovis (ANVS) shares rose 76% on July 2 after its late-stage Parkinson's disease study showed significant results on primary and secondary goals for its drug, buntanetap.
Why It Matters - Annovis's significant stock surge reflects investor confidence in its drug's efficacy, potentially leading to increased market value and future revenue from successful commercialization.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
